These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35196204)

  • 1. Optimised point estimators for multi-stage single-arm phase II oncology trials.
    Grayling MJ; Mander AP
    J Biopharm Stat; 2022 Nov; 32(6):817-831. PubMed ID: 35196204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of secondary endpoints in two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point estimation following a two-stage group sequential trial.
    Grayling MJ; Wason JM
    Stat Methods Med Res; 2023 Feb; 32(2):287-304. PubMed ID: 36384365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation and expected sample size in Simon's two-stage designs that stop as early as possible.
    Daletzakis A; van den Bor R; Jonker MA; Roes KCB; van Tinteren H
    Pharm Stat; 2022 Sep; 21(5):879-894. PubMed ID: 35191174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusting for treatment selection in phase II/III clinical trials with time to event data.
    Khan JN; Kimani PK; Glimm E; Stallard N
    Stat Med; 2023 Jan; 42(2):146-163. PubMed ID: 36419206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics.
    Verbeeck J; Deltuvaite-Thomas V; Berckmoes B; Burzykowski T; Aerts M; Thas O; Buyse M; Molenberghs G
    Stat Methods Med Res; 2021 Mar; 30(3):747-768. PubMed ID: 33256560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What inference for two-stage phase II trials?
    Porcher R; Desseaux K
    BMC Med Res Methodol; 2012 Aug; 12():117. PubMed ID: 22867439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A note on point estimation of the hazard ratio in exponential distributions.
    Lui KJ; Rhodes P
    Stat Med; 1990 Oct; 9(10):1167-73. PubMed ID: 2247717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the odds ratio from multi-stage randomized trials.
    Cao S; Jung SH
    Pharm Stat; 2024 Mar; ():. PubMed ID: 38462496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints.
    Di Stefano F; Pannaux M; Correges A; Galtier S; Robert V; Saint-Hilary G
    Stat Med; 2022 May; 41(10):1767-1779. PubMed ID: 35098579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bias of the sample proportion following a group sequential phase II clinical trial.
    Chang MN; Wieand HS; Chang VT
    Stat Med; 1989 May; 8(5):563-70. PubMed ID: 2727475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.
    Guo HY; Liu A
    J Biopharm Stat; 2005; 15(5):773-81. PubMed ID: 16078384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computation of the uniform minimum variance unbiased estimator of a normal mean following a group sequential trial.
    Emerson SS
    Comput Biomed Res; 1993 Feb; 26(1):68-73. PubMed ID: 8444028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review.
    Shimura M; Nomura S; Wakabayashi M; Maruo K; Gosho M
    JAMA Netw Open; 2020 Jun; 3(6):e208633. PubMed ID: 32573709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints.
    Sun Y; Zhang X; Tan X; Tu D
    Contemp Clin Trials; 2021 Jun; 105():106390. PubMed ID: 33819639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.